BrainStorm Announces CEO Interview With The Wall Street Analyst

BrainStorm Announces CEO Interview With The Wall Street Analyst 
NEW YORK, NY and PETACH TIKVAH, ISRAEL -- (Marketwired) -- 05/23/13
--   BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer
of adult stem cell technologies for neurodegenerative diseases,
announced that The Wall Street Analyst conducted an audio interview
yesterday with the Company's Chief Executive Officer Alon Natanson.
The interview can be heard on The Wall Street Analyst website at the
following link: 
Topics discussed by Mr. Natanson include an update on the Company's
NurOwn(TM) stem cell technology and its use in current and upcoming
clinical trial activities. Specifically, Mr. Natanson discussed the
very encouraging observations in the Company's recently completed
Phase I/II trial, advances in the ongoing Phase IIa clinical trial
and plans for the upcoming Phase II trial, expected to begin later
this year in the U.S. at sites including Massachusetts General
Hospital, UMass Hospital and the Mayo Clinic. 
During the interview Mr. Natanson commented, "As far as companies in
this field go, I think we've progressed more quickly than anyone,
having successfully completed a Phase I trial in only a year and a
half, and moved ahead immediately to Phase II, which should conclude
later this year. To achieve all this in only 2 1/2 years is extremely
fast. We hope to run our upcoming US trial at an equally fast pace,
as we feel we are in a race to beat this disease and get our product
to the market as quickly as possible." 
About The Wall Street Analyst
 The Wall Street Analyst conducts
unbiased, unfiltered and candid interviews with management of
publicly traded companies to unlock possible investment opportunities
before the rest of the market discovers them. The WSA's staff of
writers, analysts, publishers, producers, market researchers and PR
professionals aim to provide investors with the tools they need to
make informed decisions on buying stock and its audience consists of
retail and institutional investors, analysts, fund managers and
members of the financial press. For more information, visit  
About BrainStorm Cell Therapeutics, Inc.
 BrainStorm Cell
Therapeutics, Inc. is a biotechnology company engaged in the
development of first-of-its-kind adult stem cell therapies derived
from autologous bone marrow cells for the treatment of
neurodegenerative diseases. The Company holds the rights to develop
and commercialize its NurOwn technology through an exclusive,
worldwide licensing agreement with Ramot, the technology transfer
company of Tel Aviv University. For more information, visit the
company's website at  
Safe Harbor Statement -- Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics, Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended to
identify these forward-looking statements. The potential risks and
uncertainties include, without limitation, risks associated with
BrainStorm's limited operating history, history of losses; minimal
working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to obtain
required regulatory approvals; and other factors detailed in
BrainStorm's annual report on Form 10-K and quarterly reports on Form
10-Q available at These factors should be
considered carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the beliefs,
expectations and opinions of management as of the date of this press
release. We do not assume any obligation to update forward-looking
statements to reflect actual results or assumptions if circumstances
or management's beliefs, expectations or opinions should change,
unless otherwise required by law. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. 
BrainStorm Cell Therapeutics Inc. 
Mr. Alon Natanson
Phone: +972-3-9236384  
LifeSci Advisors, LLC
Michael Rice
Founding Partner
Phone: 646-597-6979 
Press spacebar to pause and continue. Press esc to stop.